Panacea Biotec Bags ₹127 Crore Polio Vaccine Supply Deal from Government

Panacea Biotec has received a new order worth ₹127.20 crore from the Central Medical Services Society (CMSS) under the Ministry of Health and Family Welfare for the supply of bivalent oral polio vaccines (bOPV). 

The order highlights the company’s continued contribution to India’s immunisation programmes and aligns with the government’s ongoing efforts to maintain the country’s polio-free status. 

The supply will be executed in several tranches over a period of 90 to 480 days from the date of the Letter of Acceptance (LoA), issued on October 8, 2025.

Supporting India’s Ongoing Polio-Free Mission

The CMSS, an autonomous body under the Ministry of Health, is responsible for centralised drug procurement and distribution across India’s health programmes. Through this contract, Panacea Biotec will support the national immunisation initiative that has played a vital role in India maintaining its polio-free certification since 2014.

Global Vaccine Supply Partnership

In addition to the domestic order, the company has also secured an international deal from the United Nations International Children’s Emergency Fund (UNICEF). The Letter of Award (LoA), issued on October 3, is part of a long-term agreement to supply bOPV in 10 and 20-vial presentations between April 2026 and March 2030. 

The total contract value for 2026–2027 stands at approximately $35.65 million (around ₹315 crore), with supplies scheduled to be completed by 2027.

Panacea Biotec Share Price Performance

As of 3:04 PM IST on October 9, 2025, Panacea Biotec share price was trading at ₹439.15, marking an increase of ₹8.00 or 1.86% from the previous close of ₹431.15. The stock opened at ₹436.50 and moved within a day’s range of ₹428.05 to ₹445.05, with a trading volume of 1,68,315 shares. 

Over the past 52 weeks, Panacea Biotec share price has ranged between ₹271.20 and ₹581.90. The company’s market capitalisation currently stands at ₹2,641.44 crore.

Read more: Indosolar Share Price Surges Nearly 5% Ahead of Declaring Q2 FY26 Earnings Results

Conclusion

Panacea Biotec’s recent domestic and international vaccine supply contracts reinforce its role in public health and vaccine manufacturing. With continued participation in both national and global immunisation programmes, the company remains aligned with India’s long-term healthcare goals and export growth potential.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.